{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T16:10:12Z","timestamp":1772122212820,"version":"3.50.1"},"reference-count":52,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Health Science Reports"],"published-print":{"date-parts":[[2024,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background and Aims<\/jats:title><jats:p>In the United States, the opioid epidemic has led many young people who use opioids to initiate injection drug use, putting them at risk for hepatitis C virus (HCV) infection. However, community surveys to monitor HCV prevalence among young people who inject drugs (YPWID) are rare.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>As part of Staying Safe (Ssafe), a trial to evaluate an HCV\u2010prevention intervention, a community\u2010recruited sample of 439 young people who use opioids (ages 18\u221230) in New York City (NYC) were screened from 2018 to 2021. Screening procedures included a brief verbal questionnaire, a visual check for injection marks, onsite urine drug testing, rapid HCV antibody (Ab) testing, and dried blood spot (DBS) collection. DBS specimens were sent to a laboratory for HCV RNA testing and phylogenetic analysis to identify genetic linkages among HCV RNA\u2010positive specimens. Multivariable logistic regression was used to assess associations between HCV status (Ab and RNA) and demographics and drug use patterns.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Among the 330 participants who reported injecting drugs (past 6 months), 33% (<jats:italic>n<\/jats:italic>\u2009=\u2009110) tested HCV Ab\u2010positive, 58% of whom (<jats:italic>n<\/jats:italic>\u2009=\u200964) had HCV RNA\u2010positive DBS specimens, indicating active infection. In multivariable analysis, visible injection marks (AOR\u2009=\u20093.02; <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001), older age (AOR\u2009=\u20091.38; <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.05), and female gender (AOR\u2009=\u20091.69; <jats:italic>p<\/jats:italic>\u2009=\u20090.052) were associated with HCV Ab\u2010positive status. Visible injection marks were also associated with HCV RNA\u2010positive status (AOR\u2009=\u20095.24; <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.01). Twenty\u2010five percent of RNA\u2010positive specimens (14\/57) were genetically linked.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The relatively low prevalence of active infection suggests the potential impact of treatment\u2010as\u2010prevention in reducing HCV prevalence among YPWID. Targeted community serosurveys could help identify actively infected YPWID for treatment, thereby reducing HCV incidence and future transmissions.<\/jats:p><\/jats:sec>","DOI":"10.1002\/hsr2.2211","type":"journal-article","created":{"date-parts":[[2024,7,2]],"date-time":"2024-07-02T04:35:08Z","timestamp":1719894908000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["HCV prevalence and phylogenetic characteristics in a cross\u2010sectional, community study of young people who inject drugs in New York City: Opportunity for and threats to HCV elimination"],"prefix":"10.1002","volume":"7","author":[{"given":"Mateu\u2010Gelabert","family":"Pedro","sequence":"first","affiliation":[{"name":"CUNY Graduate School of Public Health and Health Policy New York City New York USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-7510-3384","authenticated-orcid":false,"given":"Pratt","family":"Seanna","sequence":"additional","affiliation":[{"name":"CUNY Graduate School of Public Health and Health Policy New York City New York USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guarino","family":"Honoria","sequence":"additional","affiliation":[{"name":"CUNY Graduate School of Public Health and Health Policy New York City New York USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hallack","family":"Renee","sequence":"additional","affiliation":[{"name":"NYS Department of Health Wadsworth Center Albany New York USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fong","family":"Chunki","sequence":"additional","affiliation":[{"name":"CUNY Graduate School of Public Health and Health Policy New York City New York USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eckhardt","family":"Ben","sequence":"additional","affiliation":[{"name":"NYU School of Medicine New York City New York USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2024,7]]},"reference":[{"key":"e_1_2_10_2_1","unstructured":"JonesCM LoganJ GladdenMR BohmM. Vital signs: demographic and substance use trends among heroin users\u2014United States 2002\u20132013 [Internet].2015;64:719\u2010725.https:\/\/www.cdc.gov\/mmwr\/preview\/mmwrhtml\/mm6426a3.htm"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.addbeh.2018.04.017"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2015.03.039"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cis393"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1086\/649783"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1086\/588297"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-144-10-200605160-00004"},{"key":"e_1_2_10_9_1","unstructured":"2021 Hepatitis C | Viral hepatitis surveillance report | CDC [Internet].2023Accessed April 16 2024.https:\/\/www.cdc.gov\/hepatitis\/statistics\/2021surveillance\/hepatitis-c.htm"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2004.01.014"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2008.12.007"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2009.12.028"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.addbeh.2011.12.001"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiz142"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1086\/605947"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1097\/00126334-200406010-00012"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwn237"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiq111"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2022.835836"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(17)30676-X"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1515195"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciab596"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiaa100"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.27310"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2893.2010.01297.x"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2007.05.007"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2018.08.004"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12864-017-4268-3"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.01521-08"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiv542"},{"key":"e_1_2_10_31_1","doi-asserted-by":"crossref","unstructured":"AkiyamaM KhudyakovY RamachandranS et al. Country\u2010wide hepatitis C virus transmission networks among people who inject drugs in Kenya [Internet]; 2024. Accessed April 23 2024.https:\/\/papers.ssrn.com\/abstract=4700104","DOI":"10.2139\/ssrn.4700104"},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.2105\/AJPH.2014.302142"},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2021.108527"},{"key":"e_1_2_10_34_1","doi-asserted-by":"publisher","DOI":"10.1177\/0033354920921817"},{"key":"e_1_2_10_35_1","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.13437"},{"key":"e_1_2_10_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2019.02.008"},{"key":"e_1_2_10_37_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11606-020-05701-9"},{"key":"e_1_2_10_38_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-016-1807-5"},{"key":"e_1_2_10_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(12)70010-5"},{"key":"e_1_2_10_40_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0226166"},{"key":"e_1_2_10_41_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11904-018-0406-z"},{"key":"e_1_2_10_42_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2022.0170"},{"key":"e_1_2_10_43_1","unstructured":"NYC Health. Epi data brief: syringe service programs in New York City. NYCDOHMH; 2019."},{"key":"e_1_2_10_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2017.04.032"},{"key":"e_1_2_10_45_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12889-021-11492-3"},{"key":"e_1_2_10_46_1","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.13596"},{"key":"e_1_2_10_47_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000000659"},{"key":"e_1_2_10_48_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2014-004988"},{"key":"e_1_2_10_49_1","doi-asserted-by":"publisher","DOI":"10.1093\/jurban\/jtg137"},{"key":"e_1_2_10_50_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(23)00018-3"},{"key":"e_1_2_10_51_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiaa442"},{"key":"e_1_2_10_52_1","doi-asserted-by":"publisher","DOI":"10.1002\/rmv.2320"},{"key":"e_1_2_10_53_1","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.13924"}],"container-title":["Health Science Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hsr2.2211","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,27]],"date-time":"2024-07-27T04:01:29Z","timestamp":1722052889000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/hsr2.2211"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":52,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["10.1002\/hsr2.2211"],"URL":"https:\/\/doi.org\/10.1002\/hsr2.2211","archive":["Portico"],"relation":{},"ISSN":["2398-8835","2398-8835"],"issn-type":[{"value":"2398-8835","type":"print"},{"value":"2398-8835","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"2024-01-15","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-06-04","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-07-01","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e2211"}}